Allergan’s Net Revenues Increase 2.8 Percent; Restasis Sales Drop 17.2 Percent

May 4, 2018: By Jon Swedien

Allergan’s Q1-2018 net revenues were $3.67 billion, a 2.8 percent increase from the same quarter in 2017, the Dublin-based company announced April 30.

Net revenues for Restasis in Q1-2018 were $255.8 million, a 17.2 percent decrease compared with the dry eye drug’s net revenues from Q1-2017. Allergan said demand growth for Restasis of 4 percent was offset by trade buying patterns and lower net selling prices.

Net revenues for Ozurdex (dexamethasone intravitreal implant), for diabetic macular edema, were $25.5 million, a 13.3 percent increase compared with Q1-2017.

Allergan reported May 3 that its board declared a cash dividend of $0.72 per ordinary share for Q2-2018. The dividend will be paid June 15 to shareholders of record at the close of business May 18, the company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023